Trails of discovery: "Penicillin for cholesterol": The bumpy ride of the discovery and development of the HMG-CoA reductase inhibitors, or statins

Dialogues in Cardiovascular Medicine

Volumn 11, Issue 4, 2006, Pages 307-314

  Fitzgerald, J Desmond ^a  

^a Materia Medica   (United Kingdom)

Author keywords

Cholesterol; CoA reductase; LDL receptor; Mevastatin

Indexed keywords

3 METHYL 4 PHENYLBUTENOIC ACID DERIVATIVE; BUTYRIC ACID DERIVATIVE; CHOLESTEROL; CITRININ; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; COMPACTIN; DEXTROTHYROXINE; FIBRIC ACID DERIVATIVE; GLUTARIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LANOSTEROL; MEVINOLIN; NEOMYCIN; NICOTINIC ACID; PENICILLIN G; PHOSPHORIC ACID TRIS(2 DIETHYLAMINOETHYL) ESTER; PHYTOSTEROL; PRAVASTATIN; SIMVASTATIN; SUCCINIC ACID DERIVATIVE; TRIPARANOL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CLINICAL OBSERVATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG STRUCTURE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; NEGATIVE FEEDBACK; NONHUMAN; UNSPECIFIED SIDE EFFECT;

EID: 34249891891     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Fitzgerald JD Trails of Discovery. A close call: The discovery of the ACE inhibitors. Dialogues Cardiovasc Med. 2000;6:38-42.
2. Fitzgerald J D. Trails of Discovery. A cornerstone of cardiovascular therapy: The thiazide diuretics. Dialogues Cardiovasc Med. 2005;10:175-182.
3. Chin-Dusting J, Mizrahi J, Jennings G, Fitzgerald JD. Finding improved medicines: The role of academic-industrial collaboration. Nat Rev Drug Discov. 2005;4:891-897.
4. Schoenheimer R, Breusch F. Synthesis and destruction of cholesterol in the organism. J Biol Chem. 1933;103:439-448.
5. Langdon RG, Bloch K. The effect of some dietary additions on the synthesis of cholesterol from acetate in vitro. J Biol Chem. 1953;202:77-81.
6. Frantz ID, Schneider HS, Hinkelman BT. Suppression of hepatic cholesterol synthesis in the rat by cholesterol feeding. J Biol Chem. 1954;206:465-469.
7. Siperstein MD, Fagan VM, Dietschey JM. A gas-liquid chromatographic procedure for the measurement of mevalonic acid synthesis. J Biol Chem. 1966;241:597-601.
8. Siperstein MD, Fagan VM. Feedback control of mevalonate synthesis by dietary cholesterol. J Biol Chem. 1966;241:602-609.
9. Goldstein JL, Dana SE, Faust AL, et al. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein, observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem. 1975;250:8487-8495.
10. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res. 2004;45:1583-1593.
11. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy. Part II: The early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res. 2005;46:179-190.
12. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy. Part III: Mechanistically defining the role of hyperlipidemia. J Lipid Res. 2005;46:2037-2051.
13. Wilkinson CF, Hand EA, Fliegleman MT. Essential familial hypercholesterolaemia. Ann Int Med. 1948;29:671-686.
14. Leren P. The Oslo Diet-Heart Study. 11-year report. Circulation. 1970;42:935-942.
15. Mann CV. Diet-heart: End of an era. N Engl J Med. 1977;297:644-650.
16. Oliver MF. Serum cholesterol- The Knave of Hearts and the Joker Lancet. 1981;2:1090-1095.
17. Fitzgerald JD Trails of Discovery. The discovery of the fibrates. Dialogues Cardiovasc Med. 2003;8:155-162.
18. Steinberg D. Chemotherapeutic approaches to the problem of hyperlipidaemia. In: Garattini S, Shore P eds. Advances in Pharmacology. New York, NY: Academic Press. 1962:59-159.
19. Holmes WL, Ditullio MW. Inhibitors of cholesterol biosynthesis which act at or beyond the mevalonic acid stage. Am J Clin Nutr. 1962;10:310-322.
20. Achor RW, Winkelmann RK, Perry HO. Cutaneous side effects from use of Triparanol (MER-29); preliminary data on ichtyosis and loss of hair. Proc Mayo Clin. 1961;36:217-221.
21. Isler O, Ruegg R, Saucey G, et al. In: Wolstenholme GE, O'Connor M, eds. Biosynthesis of Terpenes and Sterols. Boston, Mass: Little, Brown; 1959:135-149.
22. Porcellati G, Giorgini D, Foja E. Inhibition of cholesterol synthesis by β-benzal butyric acid and derivates. Resuscitation. 1998;36:29-36.
23. Boots SG, Boots MR, Guyer KE. Hypocholesterolemic agents I:3-methyl-4-phenylbutenoic acids. J Pharm Sci. 1971;60:614-616.
24. Boots MR, Boots SG, Noble CM, Guyer KE. Hypocholesterolemic agents II: Inhibition of β-hydroxy-β-methylglutaryl coenzyme A reductase by arylalkyl hydrogen succinates and glutarates. J Pharm Sci. 1973;62:952-957.
25. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc (Perkin 1). 1976;1165-1170.
26. Endo A, Kuroda M, Tsujita Y. ML-236A ML-236B and ML-236-C. New inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot. 1976;29:1346-1348.
27. Endo A, Kuroda M. Citrinin, an inhibitor of cholesterol synthesis. J Antibiot. 1988;16:241-250.
28. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
29. Sato A, Ogiso A, Noguchi H, Mitsui S, Kaneko I, Shimada Y. Mevalonolacton derivatives as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Chem Pharm Bull (Tokyo). 1980;28: 1509-1525.
30. Kuroda M, Tsujita Y, Tanzawa K, Endo A. Hypolipidaemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase. Lipids. 1979;14:585-589.
31. Fears R, Richards OH, Fears H. The effect of compactin, the potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis. 1980;35:439-449.
32. Yamanoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolaemia. Atherosclerosis. 1980;35:259-266.
33. Goldstein JL, Brown MS. Lipoprotein receptors, cholesterol metabolism and atherosclerosis. Arch Pathol. 1975;99:1811-184.
34. Brown MS. Faust JR, Goldstein JL, Kaneko I, Endo A. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem. 1978;253:1121-1128.
35. Endo, A. I finally tested a statin on myself! Atheroscler Suppl. 2004;5:31.
36. Alberts AW, Chen J, et al. Mevinolin: A highly potent competitive inhibitor of HMG-CoA reductase, a cholesterol-lowering agent Proc Natl Acad Sci U S A. 1980;77: 3957-3961.
37. Tobert JA. Lovastatin and beyond: A history of HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2:517-526.
38. Brown MS, Goldstein JL. A tribute to Akira Endo, discoverer of a "penicillin" for cholesterol. Atheroscler Suppl. 2004;5:13-16.
39. Alberts AW. Discovery, biochemistry and biology of lovastatin Am J Cardiol. 1988;62:10J-15J.
40. La Rosa C, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
41. Malik S, Kashyap ML. Dyslipidemia treatment: Current considerations and unmet needs. Exp Rev Cardiovasc. 2003;1:121-134.
42. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35-46.
43. Jain MK, Ridker PN. Anti-inflammatory effects of statins: clinical evidence and basic medicines. Nat Rev Drug Discov. 2005;4:977-987.